AAPL343.01-0.90 (-0.26%) ▼|ABBV286.49-0.37 (-0.13%) ▼|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|AAPL343.01-0.90 (-0.26%) ▼|ABBV286.49-0.37 (-0.13%) ▼|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|
12.3 C
New York
Tuesday, October 27, 2026

Tag: healthcare

newsFORsourcecompanycontentinformation1releasesmarket

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline Results – Paradigm Shift in Surgical Infection Prevention

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future 
PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future

“STRONGER TOGETHER”: SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION”, ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON...

Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth...

Anatomage Inc. Announces the Winners of the 2025 National Anatomage Tournament

SANTA CLARA, Calif., June 11, 2025 /PRNewswire/ -- Anatomage Inc., a market leader in medical education technology, has announced the winners of this year's...

Wandercraft announces Series D Round, bringing $75M in total funding secured for global acceleration of AI-powered robotics

Clinical progress, industrial partnerships, and global recognition drive momentum in rehabilitation, personal mobility, and humanoid robotics. New agreemen

SuperCom Wins New Contract Valued at up to $2.5 million in North California

Expected to Generate Approximately $500,000 in Annual Recurring Revenue and Reinforces SuperCom's Position in U.S. Public Safety Market TEL AVIV, Israel, June 11, 2025 /PRNewswire/...

Sharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ET

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Project 55 Launches Free Mental Health First Responder Training for Public Use

Evidence-informed course equips non-professionals to respond to mental health crises with practical, scalable skills

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients...

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough...

$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis 
$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis

NextNRG to Be Added to Russell 2000® and Russell 3000® Indexes

NextNRG to Be Added to Russell 2000® and Russell 3000® Indexes

Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand

HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was...

Ocugen To Present at BIO International Convention 2025

MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025.

Simtra BioPharma Solutions and MilliporeSigma Announce Strategic Alliance for Antibody Drug Conjugates Drug Substance and Drug Product Manufacturing Services

Proven leaders in biologics manufacturing are aligning their strengths to deliver a more efficient and cost-optimized drug development supply chain, worldwide Alliance aims to expedite...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealthcare

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers